Insulet Corporation (NASDAQ:PODD) Receives Average Rating of "Moderate Buy" from Analysts

Insulet Corporation (NASDAQ:PODD - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eighteen brokerages that are covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $321.00.

Several equities analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Insulet from a "buy" rating to a "hold" rating in a report on Saturday, June 14th. The Goldman Sachs Group assumed coverage on shares of Insulet in a report on Friday, May 30th. They set a "buy" rating and a $380.00 price target for the company. Citigroup reissued a "buy" rating and set a $380.00 price target (up previously from $320.00) on shares of Insulet in a report on Thursday, May 22nd. Raymond James Financial reissued an "outperform" rating and set a $360.00 price target (up previously from $328.00) on shares of Insulet in a report on Tuesday, May 27th. Finally, Oppenheimer lifted their price objective on shares of Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a research note on Friday, May 9th.

Insulet Stock Performance

Insulet stock opened at $301.14 on Monday. The company has a market cap of $21.19 billion, a PE ratio of 54.16, a P/E/G ratio of 2.69 and a beta of 1.35. The company has a fifty day moving average price of $303.07 and a two-hundred day moving average price of $279.13. The company has a debt-to-equity ratio of 1.21, a current ratio of 4.47 and a quick ratio of 3.63. Insulet has a 12 month low of $173.00 and a 12 month high of $329.33.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. The firm had revenue of $569.00 million during the quarter, compared to the consensus estimate of $543.20 million. Insulet had a net margin of 18.29% and a return on equity of 22.25%. The firm's revenue was up 28.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.73 earnings per share. Research analysts expect that Insulet will post 3.92 earnings per share for the current year.

Insider Buying and Selling

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the business's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the sale, the senior vice president owned 23,180 shares in the company, valued at approximately $7,382,134.60. The trade was a 18.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.39% of the company's stock.

Institutional Trading of Insulet

Institutional investors and hedge funds have recently bought and sold shares of the stock. Larson Financial Group LLC raised its holdings in Insulet by 426.3% during the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after buying an additional 81 shares during the period. Zions Bancorporation National Association UT acquired a new position in shares of Insulet in the 1st quarter valued at about $26,000. SouthState Corp increased its holdings in shares of Insulet by 253.3% in the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock valued at $28,000 after purchasing an additional 76 shares during the period. SBI Securities Co. Ltd. acquired a new position in shares of Insulet in the 4th quarter valued at about $36,000. Finally, Itau Unibanco Holding S.A. acquired a new position in shares of Insulet in the 4th quarter valued at about $42,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.